Risk-Adapted Follow-up After Negative MRI-Targeted Biopsy in PI-RADS 3-5 Lesions: A Clinical Cohort Study With Diagnostic Stewardship Modeling.
코호트
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
4 patients (4.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
In this study, cancer was uncommon and clinically significant disease was rare, with no cancers in PI-RADS 3 lesions. Combining MRI findings with PSA density and digital rectal examination may help identify men who can safely defer repeat biopsy.
[BACKGROUND] Optimal follow-up after a negative MRI-targeted biopsy in men with PI-RADS 3-5 lesions remains uncertain.
- Specificity 80.5%
- 연구 설계 cohort study
APA
Lagos-Beitz HE, Neri-Moguel G, et al. (2026). Risk-Adapted Follow-up After Negative MRI-Targeted Biopsy in PI-RADS 3-5 Lesions: A Clinical Cohort Study With Diagnostic Stewardship Modeling.. Clinical genitourinary cancer, 102527. https://doi.org/10.1016/j.clgc.2026.102527
MLA
Lagos-Beitz HE, et al.. "Risk-Adapted Follow-up After Negative MRI-Targeted Biopsy in PI-RADS 3-5 Lesions: A Clinical Cohort Study With Diagnostic Stewardship Modeling.." Clinical genitourinary cancer, 2026, pp. 102527.
PMID
41997766 ↗
Abstract 한글 요약
[BACKGROUND] Optimal follow-up after a negative MRI-targeted biopsy in men with PI-RADS 3-5 lesions remains uncertain. Repeat biopsy may detect missed cancers but exposes many patients to unnecessary risk. We aimed to characterize real-world outcomes and develop a risk-adapted framework.
[METHODS] We conducted a retrospective cohort study of 86 men with PI-RADS 3-5 lesions and benign index MRI-targeted biopsy. The primary outcome was detection of prostate adenocarcinoma on repeat biopsy or during surgery for benign prostatic obstruction (BPO). Clinically significant prostate cancer (csPCa) was defined as ISUP grade group ≥2. Imaging trajectories, PSMA-PET findings, and management strategies were analyzed. A baseline risk score incorporating PI-RADS 5, PSA density (PSAD), and abnormal digital rectal examination (DRE) was evaluated.
[RESULTS] During follow-up, cancer was detected in 4 patients (4.7%): two on repeat biopsy (both ISUP 1) and two incidentally at BPO surgery, including one csPCa. No cancers occurred in PI-RADS 3 lesions. PSMA-PET positivity clustered in PI-RADS 5. A baseline score ≥2 achieved 100% sensitivity and negative predictive value, with specificity of 80.5% (PSAD ≥0.15) and 85.4% (PSAD ≥0.20), potentially avoiding 76.7-81.4% of repeat procedures.
[CONCLUSIONS] Cancer detection after a negative MRI-targeted biopsy was uncommon and predominantly low grade. A risk-adapted approach may reduce unnecessary re-biopsies while preserving detection of clinically significant disease. External validation is warranted.
[PATIENT SUMMARY] Men with a suspicious prostate MRI lesion (PI-RADS 3-5) but a negative targeted biopsy often worry about missed cancer. In this study, cancer was uncommon and clinically significant disease was rare, with no cancers in PI-RADS 3 lesions. Combining MRI findings with PSA density and digital rectal examination may help identify men who can safely defer repeat biopsy.
[METHODS] We conducted a retrospective cohort study of 86 men with PI-RADS 3-5 lesions and benign index MRI-targeted biopsy. The primary outcome was detection of prostate adenocarcinoma on repeat biopsy or during surgery for benign prostatic obstruction (BPO). Clinically significant prostate cancer (csPCa) was defined as ISUP grade group ≥2. Imaging trajectories, PSMA-PET findings, and management strategies were analyzed. A baseline risk score incorporating PI-RADS 5, PSA density (PSAD), and abnormal digital rectal examination (DRE) was evaluated.
[RESULTS] During follow-up, cancer was detected in 4 patients (4.7%): two on repeat biopsy (both ISUP 1) and two incidentally at BPO surgery, including one csPCa. No cancers occurred in PI-RADS 3 lesions. PSMA-PET positivity clustered in PI-RADS 5. A baseline score ≥2 achieved 100% sensitivity and negative predictive value, with specificity of 80.5% (PSAD ≥0.15) and 85.4% (PSAD ≥0.20), potentially avoiding 76.7-81.4% of repeat procedures.
[CONCLUSIONS] Cancer detection after a negative MRI-targeted biopsy was uncommon and predominantly low grade. A risk-adapted approach may reduce unnecessary re-biopsies while preserving detection of clinically significant disease. External validation is warranted.
[PATIENT SUMMARY] Men with a suspicious prostate MRI lesion (PI-RADS 3-5) but a negative targeted biopsy often worry about missed cancer. In this study, cancer was uncommon and clinically significant disease was rare, with no cancers in PI-RADS 3 lesions. Combining MRI findings with PSA density and digital rectal examination may help identify men who can safely defer repeat biopsy.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Whole-body MRI for staging and follow-up of primary musculoskeletal tumours: a systematic review.
- Multifocal anaplastic astrocytoma mimicking primary central nervous system lymphoma: A case report.
- Lateral Tension Upper Body Lift: "Zip-Shark" Technique as Novel Procedure.